Serotonin receptor (5HTR2A) gene polymorphism has been reported to be associated with clinical phenotypes in schizophrenia. The current study attempted to investigate a relationship between 5HTR2A 102T/C polymorphism and personality traits as well as clinical symptoms in patients with ICD-10 diagnoses of schizophrenia and affective disorders. 5HTR2A genotyping, clinical and psychological assessment were administered to 375 patients, 104 first-degree healthy relatives of the patients and 157 controls. In the patients an association was observed between the 2/2 5HTR2A genotype and scores on the Hypochondriasis scale (MMPI) (ANOVA, F = 4.56; P = 0.011) and trait anxiety (F = 4.21; P = 0.002). A significant difference between 1/1 and 2/2 genotypes has been also found for Neuroticism scores (EPI) (t = 2.18; P = 0.0031). No significant differences by 5HTR2A genotype were observed in either the control or first-degree relatives group for all scales studied. Positive, negative and psychopathological symptoms emerged higher in the 2/2 genotype patients compared to other genotype carriers. Therefore, the 2/2 genotype may contribute to produce the phenotype, with specific clinical and pathological features in common, regardless of nosologic heterogeneity of psychoses.
We tested the criterion, concurrent, and content validity of depression indicators in 180 Russian psychiatric patients. Indicators from the Exner Rorschach (DEPI, CDI) and the Russian MMPI (Berezin Scale 2, Wiggins depression content) were compared to Hamilton (HRSD) scores and 3 types of diagnosis: traditional Russian, contemporary Western (ICD-10), and a mixed version. The MMPI scales had significant associations with each other and each criterion. The Rorschach indexes were unrelated to all other variables, even when their affective, cognitive, and interpersonal components were analyzed separately, response styles were taken into account, or the 2 indexes were used in combination. Nevertheless, sample means on 107 variables were roughly similar to Exner's norms. The study represents an initial step towards establishing the validity of instruments commonly used in Russia and North America for assessing depression among Russians.
Background. Both non-suicidal self-injuries (NSSIs) and suicidal attempts (SAs) in adolescence represent significant risk factors for consequent suicide, but neurophysiological markers and predictors of these two forms of auto-aggressive behavior have been studied insufficiently. Objective. The aim of the study was to identify the differences of electroencephalographic (EEG) frequency and spatial parameters between depressive female adolescents with solely NSSI, and with combined NSSI + SA behavior in their history. Methods. The study included 45 female depressive in-patients aged 16-25 years. Baseline resting EEG spectral power, asymmetry, and coherence were analyzed in 8 narrow frequency sub-bands. Results. In the NSSI + SA subgroup (n = 24), the spectral power of parietal–occipital alpha-2 (9-11 Hz) was higher than in the NSSI subgroup, its focus was localized in the right hemisphere, and alpha-3 (11-13 Hz) spectral power was higher than alpha-1 (8-9 Hz). In the NSSI subgroup (n = 21) alpha-1 spectral power was higher than alpha-3, and foci of alpha-2 and alpha-3 were localized in the left hemisphere. EEG coherence was also higher in the NSSI + SA subgroup than in the NSSI subgroup, especially in frontal–central–parietal regions. Conclusions. The spatial distribution of the EEG frequency components in the NSSI + SA subgroup reflects the greater activation of the left hemisphere that is more typical for the EEG of individuals with an increased risk for suicide. In the NSSI subgroup, the right hemisphere is relatively more activated, and EEG coherence is lower, which is more typical for EEG in depressive disorders. The results obtained suggested the use of EEG to clarify the degree of suicidal risk in depressive female adolescents with NSSI.
We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.